Close menu




December 15th, 2025 | 07:00 CET

Alibaba, Power Metallic Mines, Bayer – Spectacular twists

  • Mining
  • Commodities
  • PGEs
  • Nickel
  • ecommerce
  • Pharma
Photo credits: pixabay.com

The 2025 stock market year is drawing to a close, and the major indices are likely to finish in positive territory once again. Nevertheless, fears of a correction are growing, especially for hyped AI stocks. In addition, due to sector rotation, there are companies that could stage a year-end rally due to their favorable valuations. Stock picking is likely to be more in demand than ever in the coming months.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: ALIBABA GR.HLDG SP.ADR 8 | US01609W1027 , POWER METALLIC MINES INC. | CA73929R1055 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    Bayer – Brightening chart picture

    The crisis-ridden agricultural and pharmaceutical company continues to bottom out. After a consolidation phase lasting more than 10 years and a loss of over 87% to EUR 18.41, Bayer shares have risen significantly since November last year. They are now trading at EUR 30.60, just shy of breaking through the significant resistance level at EUR 31. A sustained break above this level would offer the share short-term upside potential to around EUR 41.

    The Leverkusen-based company received fundamental tailwind from positive Phase 3 results for the anticoagulant Asundexian, which was able to significantly reduce the risk of stroke in patients after a non-cardioembolic ischemic stroke. The once-daily drug Asundexian, in combination with antiplatelet therapy, achieved both primary efficacy and safety endpoints. The US Food and Drug Administration (FDA) has already granted the drug fast-track status.

    Bayer's head of research, Christian Rommel, spoke of an "important milestone" in the Company's commitment to innovative thrombosis prevention. Bayer now plans to hold talks with global authorities and intends to present detailed study data at a scientific congress.

    Analysts view Bayer's development positively. Goldman Sachs is maintaining its "Buy" rating and sets the target price at EUR 34.50. Analyst James Quigley calls the new data "groundbreaking" and estimates the market potential of Asundexian at around EUR 3 billion. JPMorgan, on the other hand, remains more cautious and continues to rate Bayer as "Neutral" with a price target of EUR 25. Although it sees blockbuster potential, comparative data on the competing drug Milvexian is needed to assess the market opportunities accurately.

    Power Metallic Mines – Polymetallic powerhouse with XXL potential

    The global race for strategic metals is picking up speed, and Power Metallic Mines, a Canadian exploration stock, is coming into focus as a future heavyweight in the commodities sector. The combination of high-grade discoveries, an enormous land position, and geopolitical relevance could make the Company one of the most exciting stocks in the North American commodities sector.

    Quebec is one of the world's best jurisdictions for sustainable mining. There, Power Metallic is securing a project portfolio that is rare in the junior sector in terms of size and quality. The NISK project is delivering drill results that are already reminiscent of some of the largest polymetallic discoveries of the past decades. Copper equivalent grades of up to 16% over several meters demonstrate the potential that lies in the ground here. And the 100,000-meter drill program ensures a steady flow of news.

    Meanwhile, the project area is expanding rapidly. Through acquisitions, the property has been increased by over 600% to 313 sq km. Notably, sellers such as Li-FT Power accepted payment in shares, which demonstrates confidence in the management and the quality of the project. At the same time, metallurgical tests are underway at SGS Canada, which have so far confirmed robust sulfide mineralization and, therefore, good conditions for conventional processing methods.

    The geopolitical situation further increases the project's attractiveness. Western industries are looking for independent sources of metal, while China is tightening its export policy. A diversified copper-nickel-PGE project in a secure constitutional state such as Canada is therefore of considerable strategic importance.

    Analysts see enormous catch-up potential. At a current price of CAD 0.92, multiplication potential is forecast. Roth Capital Partners recommends the stock as a "Buy" and sees a 12-month price target of CAD 3.00, while Red Cloud assigns a price target of CAD 2.50.

    Alibaba – AI app impresses

    Since the release of NVIDIA's figures last week, AI stocks have corrected sharply in some cases, and fears of a bubble forming are rife. A look at the sometimes ludicrous valuations shows that these concerns are justified. The situation is different for AI-related companies from China, which, on the one hand, still have exorbitant catch-up potential compared to their US peers, and on the other hand, can shine with fundamental surprises.

    The newly launched Qwen app, the centerpiece of the group's AI strategy, was downloaded over 10 million times in just one week.

    Qwen's rapid rise joins the list of fast-growing AI applications. While ChatGPT set a record pace three years ago and Meta's Threads gained millions of users thanks to Facebook and Instagram, Qwen is now setting new standards, especially in China. The market in China is particularly important for Alibaba, as ChatGPT is not available there.

    The downloads were communicated via WeChat after the Company bundled and modernized its existing apps for iOS and Android under the Qwen brand. Analysts see the spread as a decisive factor for Alibaba's future valuation. In the coming months, Qwen is to be expanded into a fully-fledged AI agent – including shopping integration via Taobao, maps, food delivery, travel bookings, office tools, e-commerce, education, and health services. Group CEO Eddie Wu aims to transform Alibaba into an AI-centric tech giant.


    The Bayer share continues to work on a long-term bottom. Alibaba scored a surprise success with the launch of the Qwen app. Several analysts see significant multiplication potential in Power Metallic Mines.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Armin Schulz on September 16th, 2026 | 07:15 CEST

    Central Banks Buy Record Amounts: Newmont, Lahontan Gold and Agnico Eagle Could Be the Biggest Winners

    • Mining
    • Gold
    • Silver
    • Commodities

    Gold hit an all-time high of USD 5,589 in January 2026 before taking a breather. Currently, the metal is holding steady above USD 4,000. Central banks have been a major driver of this trend recently. In the second quarter, they made net purchases of 289 metric tons of gold, up 62% from the previous year, with Poland alone buying 51 metric tons. On September 15, the Fed will decide on interest rates, while money has also been flowing back into gold ETFs since the end of July. We are therefore taking a look at three companies – Newmont, Lahontan Gold and Agnico Eagle – that cover the full spectrum of the gold industry, from a heavyweight through a developer on the path to becoming a producer to an established gold miner.

    Read

    Commented by Carsten Mainitz on September 15th, 2026 | 10:30 CEST

    New Approaches to Fighting Cancer: Why Vidac Pharma, BioNTech and Evotec Deserve Attention

    • Biotech
    • Biotechnology
    • Cancer
    • Pharma

    Cancer cells use sophisticated defence mechanisms to evade the immune system and reprogram their own metabolism. These mechanisms are now increasingly being targeted by biotech companies. BioNTech has more than EUR 16 billion in cash and is driving the next generation of immunotherapies. Evotec is scaling up drug development through strong alliances but has eroded investor confidence. This skepticism is weighing on its share price. Developments at Vidac Pharma are particularly exciting. The company focuses on the metabolic reprogramming of malignant cells. Results from a potentially groundbreaking Phase 2b trial are imminent. Which approach offers the greatest promise?

    Read

    Commented by Jens Castner on September 15th, 2026 | 08:00 CEST

    Chronically Undervalued: When Will the Knot Finally Break for Mountain Alliance, Lahontan Gold and Mercedes-Benz?

    • Mining
    • Gold
    • Silver
    • Commodities
    • Automotive

    Some companies are brimming with substance – and yet their share prices barely move. Three current examples illustrate different forms of this phenomenon. Mountain Alliance is an investment company whose portfolio is worth significantly more than its share price suggests; Lahontan Gold is an explorer whose freely accessible precious-metal resources far exceed its market capitalization; and Mercedes-Benz is a classic that investors are currently shying away from due to political and economic concerns. Undervaluation is rarely a coincidence; rather, it has tangible causes. But there are equally tangible arguments for a re-rating.

    Read